BAL Pharma Limited announces resilient revenue growth for Q2 & H1FY23 results, against price volatility and intense API competition ...Middle East

BAL Pharma Limited, a fully integrated pharmaceuticals Company specialising in Bulk Drugs, Prescription Drugs, Generics, and pharma intermediates, has announced its results for the Quarter that ended September 30, 2022.

Hence then, the article about bal pharma limited announces resilient revenue growth for q2 h1fy23 results against price volatility and intense api competition was published today ( Thursday 17/11/2022 - 02:01 PM ) and is available on Devdiscourse ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( BAL Pharma Limited announces resilient revenue growth for Q2 & H1FY23 results, against price volatility and intense API competition )

Also on site :

• Uncovering China’s dark drive to feed US data-center fears
• Voices: For climate-change deniers, the heat is on
• Public support for Gavin Newsom’s EV mandate breaks down, and no wonder